Skip to content

Richard Porter

3 papers in the library · 14 citations · publishing 2007-2024

Papers

Sort Most recent Most cited

Protocol for a randomised controlled trial of ketamine versus ketamine and behavioural activation therapy for adults with treatment-resistant depression in the community.

BMJ Open May 1, 2024 Ben Beaglehole, Richard Porter, Katie Douglas et al. 5 citations

Although short-term benefits follow parenteral ketamine for treatment-resistant major depressive disorder (TR-MDD), there are challenges that prevent routine use of ketamine by clinicians. These include acute dissociative effects of parenteral ketamine, high relapse rates following ketamine dosing and the uncertain role of psychotherapy. This randomised controlled trial (RCT) seeks to establish...

Multidisciplinary development of guidelines for ketamine treatment for treatment-resistant major depression disorder for use by adult specialist mental health services in New Zealand

BJPsych Open October 13, 2023 Ben Beaglehole, Paul Glue, Mike Clarke et al. 9 citations

Background The evidence base for racemic ketamine treatment for treatment-resistant major depressive disorder (TRD) continues to expand, but there are major challenges translating this evidence base into routine clinical care. Aim To prepare guidelines for ketamine treatment of TRD that are suitable for routine use by publicly funded specialist mental health services. Method We consulted with...

The relationship between non‐acute adolescent cannabis use and cognition

Drug and Alcohol Review May 1, 2007 Megan A. Harvey, John D. Sellman, Richard Porter et al.

AbstractResearch indicates that cannabis continues to be a popular illegal drug internationally. Furthermore, adolescent rates of use appear to be significant. Whilst the non‐acute effect of cannabis use on adult cognition has been extensively researched, there has been less examination of adolescents. This study aimed to investigate the non‐acute relationship between cannabis and cognitive...